Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934150 | 0.95 | CCR2 (0.67) | CCR2 | |
| SCHEMBL15123571 | 0.87 | CCR2 (0.56) | CCR2 | |
| SCHEMBL15123288 | 0.83 | CCR2 (0.52) | CCR2 | |
| SCHEMBL15123469 | 0.82 | CCR2 (0.52) | CCR2KCNH2 | |
| SCHEMBL9934209 | 0.81 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL9934374 | 0.80 | CCR2 (0.69) | CCR2KCNH2 | |
| SCHEMBL9933068 | 0.79 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL19336561 | 0.78 | CCR2 (0.45) | CCR2 | |
| SCHEMBL9934019 | 0.78 | CCR2 (0.69) | CCR2 | |
| SCHEMBL9933541 | 0.76 | CCR2 (1.00) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | claimed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | claimed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | claimed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | claimed |
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-03-24 | — | — | US | claimed |
| EP-2651893-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083342-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885KCNH2 4770/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885KCNH2 4770/4885 |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885KCNH2 4770/4885 |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | CCR2 3/4885KCNH2 4770/4885 |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | CCR2 3/4885KCNH2 4770/4885 |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | CCR2 3/4885KCNH2 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.